BLU · BELLUS Health Inc.

-

Please sign in to comment on BLU

1 Comment

Admin

4 years ago

BELLUS Health Inc is currently in a long term downtrend where the price is trading 14.0% below its 200 day moving average.

From a valuation standpoint, the stock is 1054.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15464.1.

BELLUS Health Inc's total revenue sank by 44.1% to $4K since the same quarter in the previous year.

Its net income has increased by 27.2% to $-7M since the same quarter in the previous year.

Finally, its free cash flow grew by 1.6% to $-10M since the same quarter in the previous year.

Based on the above factors, BELLUS Health Inc gets an overall score of 2/5.

ISIN	CA07987C2040
Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD

Market Cap	2B
PE Ratio	None
Target Price	16.06
Dividend Yield	0.0%
Beta	-0.28

ABOUT

BELLUS Health Inc.

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

BLU · BELLUS Health Inc.

-

BELLUS Health Inc.

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest BELLUS Health Inc. using a moving average strategy